NO991194D0 - Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid - Google Patents
Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydrokloridInfo
- Publication number
- NO991194D0 NO991194D0 NO991194A NO991194A NO991194D0 NO 991194 D0 NO991194 D0 NO 991194D0 NO 991194 A NO991194 A NO 991194A NO 991194 A NO991194 A NO 991194A NO 991194 D0 NO991194 D0 NO 991194D0
- Authority
- NO
- Norway
- Prior art keywords
- alfa
- methoxyimino
- azabicyclo
- oct
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
| PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO991194D0 true NO991194D0 (no) | 1999-03-11 |
| NO991194L NO991194L (no) | 1999-03-11 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO991194A NO991194L (no) | 1996-09-12 | 1999-03-11 | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (es) |
| JP (1) | JP2001500150A (es) |
| KR (1) | KR20000036039A (es) |
| CN (2) | CN1235544A (es) |
| AR (1) | AR008176A1 (es) |
| AU (1) | AU724086B2 (es) |
| BR (1) | BR9711734A (es) |
| CA (1) | CA2265661A1 (es) |
| CO (1) | CO5031291A1 (es) |
| CZ (1) | CZ83299A3 (es) |
| GB (1) | GB9619074D0 (es) |
| HU (1) | HUP9904401A3 (es) |
| ID (1) | ID19589A (es) |
| IL (1) | IL128781A0 (es) |
| MA (1) | MA24359A1 (es) |
| NO (1) | NO991194L (es) |
| NZ (1) | NZ334268A (es) |
| PE (1) | PE2499A1 (es) |
| PL (1) | PL332074A1 (es) |
| TR (1) | TR199900505T2 (es) |
| WO (1) | WO1998010762A2 (es) |
| ZA (1) | ZA978133B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| IL138192A0 (en) | 1998-03-11 | 2001-11-25 | Smithkline Beecham Plc | Controlled release oral dosage forms |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| MY142204A (en) | 2002-07-25 | 2010-10-29 | Pharmacia Corp | Pramipexole once-daily dosage form |
| WO2004096208A1 (en) * | 2003-04-25 | 2004-11-11 | Mitsubishi Pharma Corporation | Composition for oral administration containing alkylene dioxybenzene derivative |
| DE602004002405T3 (de) * | 2003-05-14 | 2013-06-20 | Aptalis Pharma Limited | Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| CN101005830B (zh) | 2004-08-13 | 2010-09-29 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放片剂、其制备方法及用途 |
| NZ553645A (en) * | 2004-08-13 | 2010-09-30 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0392803B1 (en) * | 1989-04-13 | 2004-06-16 | Beecham Group p.l.c. | Novel compounds |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194L/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9904401A3 (en) | 2001-03-28 |
| MA24359A1 (fr) | 1998-07-01 |
| HUP9904401A2 (hu) | 2000-06-28 |
| IL128781A0 (en) | 2000-01-31 |
| CO5031291A1 (es) | 2001-04-27 |
| EP0929301A2 (en) | 1999-07-21 |
| BR9711734A (pt) | 1999-08-24 |
| CZ83299A3 (cs) | 1999-08-11 |
| WO1998010762A3 (en) | 1998-06-04 |
| ZA978133B (en) | 1999-04-12 |
| CN1446535A (zh) | 2003-10-08 |
| GB9619074D0 (en) | 1996-10-23 |
| AU724086B2 (en) | 2000-09-14 |
| WO1998010762A2 (en) | 1998-03-19 |
| CN1235544A (zh) | 1999-11-17 |
| CA2265661A1 (en) | 1998-03-19 |
| AR008176A1 (es) | 1999-12-09 |
| AU4128897A (en) | 1998-04-02 |
| PL332074A1 (en) | 1999-08-30 |
| TR199900505T2 (es) | 1999-06-21 |
| NZ334268A (en) | 2000-10-27 |
| PE2499A1 (es) | 1999-03-24 |
| NO991194L (no) | 1999-03-11 |
| ID19589A (id) | 1998-07-23 |
| KR20000036039A (ko) | 2000-06-26 |
| JP2001500150A (ja) | 2001-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991194D0 (no) | Kontrollert-frigj°ring doseform av [R-(Z)-<alfa>-(metoksyimino)-<alfa>-(azabisyklo[2,2,2]okt-3-yl)acetonitril monohydroklorid | |
| IL145071A0 (en) | Fused ring compounds and pharmaceutical compositions containing the same | |
| DE69514087D1 (de) | Pharmazeutisch aktive substituierte aromatische verbindungen | |
| IL137445A0 (en) | Pharmaceutically active compounds and methods of use thereof | |
| NO990944D0 (no) | Tablett med kontrollert frigivelse av alfuzosinhydroklorid | |
| IL110014A0 (en) | Solid controlled-release oral dosage forms | |
| HUP0004926A3 (en) | 1-(n-phenylaminoalkyl)-piperazine derivatives substituted at position 2 of the phenyl ring, pharmaceutical compositions containing them and their use | |
| EA200200571A1 (ru) | Новая композиция и ее применение | |
| HU9800112D0 (en) | Biphenyl-sulfonyl-substituted heterocyclic compounds of fife-membered ring, their production and use | |
| HUP9901590A3 (en) | Substituted aza- and diazacycloheptane and cyclooctane derivatives, use thereof, pharmaceutical compositions containing these compounds | |
| EA200200119A1 (ru) | β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ | |
| EP1115396A4 (en) | PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF | |
| PL356769A1 (en) | Novel heterocyclic compounds and salts thereof and medicinal use of the same | |
| NO986086D0 (no) | FremgangsmÕte for fremstilling av 17-estere av 9<alfa>,21-dihalo-pregnan-11 | |
| NO971997D0 (no) | Bruk av immunmodulerende midler | |
| EE200100656A (et) | Kristallilise asabitsüklo(2,2,2)oktaan-3-amiintsitraadi polümorfid ja nende ravimsegud | |
| ITMI911604A0 (it) | Procedimento per la preparazione della n- (2,6-diclorofenil) -n-feniln- (cloroacetil) - ammina | |
| NO992668D0 (no) | Topisk preparat for innf°ring av farmas°ytisk aktive peptidforbindelser i levende organismer | |
| NO20011480L (no) | Fremgangsmåte for fremstilling av (-)<alfa>- (difluormetyl)ornitin-monohydrokloridmonohydrat | |
| NO910372L (no) | Fremgangsmaate for fremstilling av heksahydropyrrolo(2,3-b)indolkarbamater-, urea-, amider og beslektede forbindelser og deres anvendelse som medikamenter. | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| NO20010195L (no) | Fremgangsmåte for behandling | |
| HUP0004734A3 (en) | Novel pharmaceutically active compounds, their preparation and use as ece-inhibitors | |
| FI933872A (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 1,3,4-bensotriazepin-5(4H)-on-derivat | |
| GB9821967D0 (en) | Process for the preparation of orally active cephalosporin antibiotic-cefixim |